Işık Tekin

Dr. Işık Tekin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2025 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
ITIşık Tekin
Işık Tekin
GGGulsah Gundogdu
Gulsah Gundogdu
OKOzgen Kilic-Erkek
Ozgen Kilic-Erkek
IBIpek Buber
Ipek Buber
HAHasan Akca
Hasan Akca
GMGülçin Mete
Gülçin Mete

3 March 2026 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
ITIşık Tekin
Işık Tekin
IBİpEk Büber
İpEk Büber
EAEsin AVCI
Esin AVCI
Objectives: Endothelial dysfunction plays a pivotal role in the pathophysiology of acute coronary syndromes (ACS), contributing to vascular instability and impaired perfusion. The endothelial activation and stress index (EASIX), originally developed for hematologic conditions as a marker of endothelial stress, has recently attracted interest in cardiovascular prognostication. However, its utility in ACS remains insufficiently defined. This study aimed to evaluate the prognostic performance of the original EASIX and its simplified (s-EASIX) and modified (m-EASIX) variants in predicting 30-day in-hospital mortality in ACS patients. Methods: We retrospectively analyzed 368 patients with ACS admitted to a coronary intensive care unit between June 2022 and June 2024. EASIX-based scores were calculated from admission laboratory parameters. The primary endpoint was all-cause in-hospital mortality, defined as death occurring during hospitalization or within 30 days of admission. Predictive accuracy was assessed using receiver operating characteristic (ROC) curve analysis, multivariate Cox regression, and model fit via Akaike information criterion (AIC). Results: In-hospital mortality occurred in 19 patients (5.2 %). All three scores were significantly higher among non-survivors (p<0.01). m-EASIX demonstrated the highest AUC (0.818) and sensitivity (88.2 %), followed by EASIX (AUC: 0.789) and s-EASIX (AUC: 0.709). In multivariate Cox analysis adjusted for conventional clinical variables, all scores independently predicted mortality, with s-EASIX yielding the highest hazard ratio (HR=2.149; p<0.01). EASIX achieved the best model fit (AIC=123.123). Conclusions: EASIX and its variants are independent predictors of short-term mortality in ACS. Among them, the original EASIX exhibited the most consistent overall performance, supporting its potential role in early risk stratification of critically ill cardiac patients.

9 April 2025 in Interventional Cardiology Perspectives
Verified
Journal Article
Open access
ITIşık Tekin
Işık Tekin
YYYalın Tolga Yaylalı
Yalın Tolga Yaylalı
GYGüzin Fidan Yaylalı
Güzin Fidan Yaylalı
Effects of Sodium-glucose Co-transporter-2 Inhibitors on Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction - Interventional Cardiology Perspectives

9 December 2024 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
IBIpek Büber
Ipek Büber
MAMuhammed Rasid Aykota
Muhammed Rasid Aykota
CSCihan İlYas Sevgican
Cihan İlYas Sevgican
DKDerya Kaya
Derya Kaya
HAHarun Akarsu
Harun Akarsu
IKIsmail Dogu Kılıc
Ismail Dogu Kılıc

9 September 2020 in e-Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
SŞSara Çetin Şanlıalp
Sara Çetin Şanlıalp
ITIşık Tekin
Işık Tekin
MŞMusa Şanlıalp
Musa Şanlıalp

22 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AOAlten Oskay
Alten Oskay
TOTulay Oskay
Tulay Oskay
VAVeli Kaan Aydin
Veli Kaan Aydin
ÖEÖzer Eser
Özer Eser
MSMurat Seyit
Murat Seyit
Aylin KöselerAylin Köseler
Aylin Köseler
Background/Objectives: Cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP3A4) play a key role in interindividual variability in cardiovascular drug metabolism. This study aimed to describe metabolizer phenotype distributions in a Turkish emergency cardiac cohort and across diagnostic categories. Methods: This retrospective descriptive pharmacogenomic study included 250 patients. Genotyping was performed using TaqMan assays for CYP2D6 (*2, *4, *10, *41), CYP2C19 (*2, *17), and CYP3A4 (*22, *1B). Phenotypes were assigned according to CPIC guidelines. CYP2D6 copy-number variation was not assessed. Results: Non-normal metabolizer phenotypes were observed in 55.6% (CYP2D6), 84.4% (CYP2C19), and 30.4% (CYP3A4) of patients. For CYP2D6, normal (44.4%) and intermediate (42.0%) metabolizers predominated. For CYP2C19, intermediate metabolizers were most frequent (36.0%), followed by normal (22.8%), rapid (17.2%), poor (14.8%), and ultra-rapid metabolizers (9.2%). CYP3A4 showed predominantly normal activity (69.6%). Phenotype distributions varied across diagnoses without clear clustering. Conclusions: A high prevalence of CYP2D6 and CYP2C19 variability with predicted functional relevance based on CPIC was observed, whereas CYP3A4 activity was more stable. These findings provide descriptive pharmacogenomic data to support future genotype-guided cardiovascular therapy studies.